Peptides While Breastfeeding or Pregnant: What You Need to Know

Key Takeaways

• Safety context: Safety data for therapeutic peptides in pregnancy ranges from robust for insulin (decades of controlled trial data) to insufficient for GLP-1 receptor agonists (limited human data, concerning animal data) to essentially absent for GH secretagogues and research-use-only compounds.
• Primary safety signals: Animal studies have shown adverse fetal outcomes with GLP-1 receptor agonist exposure; human observational data is limited and cannot be interpreted as safety clearance; no GH secretagogue or research peptide has any published reproductive safety data.
• Evidence quality summary: Most human pregnancy data for GLP-1 agents comes from observational cohorts with limited sample sizes and follow-up; animal data provides the primary mechanistic concern; no randomized controlled trials of therapeutic peptides in pregnant or breastfeeding populations have been conducted.
• Provider framing: Every decision about peptide use during pregnancy or breastfeeding must involve a qualified OB/GYN and the prescribing provider; this article provides context for that conversation, not a substitute for it.

Why Pregnancy and Breastfeeding Change the Safety Calculus

Therapeutic peptides affect biological pathways that play active roles in fetal development and lactation physiology. This is not a theoretical concern: endogenous peptide hormones regulate placental function, fetal growth, nutrient partitioning, and neonatal feeding. Bowman and colleagues, in a 2010 review in Birth Defects Research Part B, IGF axis activity in embryo-fetal development, contextualizing why growth hormone-related peptide use during pregnancy carries developmental implications even when specific harms are not yet fully characterized. Uvnäs Moberg and colleagues, in a 2020 systematic review in PLOS ONE, maternal plasma oxytocin regulation during breastfeeding through endogenous peptide mechanisms — illustrating why exogenous peptide use during lactation introduces biological variables that have not been studied.

The core challenge is not that therapeutic peptides are known to cause harm in pregnancy or during breastfeeding. It is that, for most compound classes, the evidence needed to establish safety does not exist. Most unapproved therapeutic peptides (including BPC-157, TB-500, and similar research peptides) lack any published reproductive toxicology or human pregnancy/lactation safety data, reflecting the absence of FDA-mandated preclinical studies that accompany approved drug development. The absence of data is not evidence of safety; it is the justification for caution.

FDA-approved drugs carry pregnancy and lactation risk summaries under the 2014 Pregnancy and Lactation Labeling Rule (PLLR, 21 CFR § 201.57(c)(9)), which replaced the older A/B/C/D/X pregnancy categories with narrative risk summaries based on human and animal data. Insulin formulations, GLP-1 receptor agonists, and tirzepatide carry PLLR-compliant pregnancy and lactation sections in their FDA-approved labeling. Compounded peptides (GH secretagogues, research-use-only compounds, and most other therapeutic peptides discussed below) are not FDA-approved and therefore carry no PLLR labeling; any statements about their pregnancy or lactation safety reflect absence of data, not regulatory evaluation.

The evidence quality for each compound class covered below is graded throughout using: [Human RCT] / [Human observational] / [Animal data] / [Insufficient data].

Peptide Safety by Compound Class: Pregnancy and Breastfeeding

The evidence base for pregnancy and breastfeeding safety is strongest for insulin, limited but partially characterized for GLP-1 receptor agonists, and essentially absent for GH secretagogues, research-use-only peptides, and most other therapeutic peptide classes.

FDA-approved insulin peptides: the established baseline

Insulin is the peptide class with the most robust pregnancy safety data, accumulated over decades of clinical use in women with type 1 and type 2 diabetes. Pollex and colleagues, in a 2011 systematic review and meta-analysis in Annals of Pharmacotherapy, insulin glargine versus NPH in pregnancy. Mathiesen and colleagues conducted a randomized controlled trial published in Diabetes Care in 2012, enrolling 310 pregnant women with type 1 diabetes to detemir versus NPH and finding comparable hypoglycemia rates and maternal and neonatal outcomes.

Insulin's safety record in pregnancy is not transferable to other peptide classes. It reflects compound-specific pharmacology, decades of human data, and FDA-approved indications covering pregnant populations. The contrast between insulin's evidence base and the evidence base for newer therapeutic peptides is the most important safety framing for this article. [Human RCT]

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)

• Pregnancy data — animal studies: Adverse fetal outcomes documented. Qiao and colleagues, in a 2024 study in American Journal of Physiology - Endocrinology and Metabolism, maternal GLP-1 activation inhibiting fetal growth in animal models, providing the primary mechanistic basis for the pregnancy caution. Drummond and colleagues, in a review in American Journal of Obstetrics and Gynecology in 2024, concluded that animal studies show adverse fetal outcomes and that limited human data precludes safety clearance. [Animal data]

• Pregnancy data — human observational: No clear congenital malformation signal detected, but data insufficient. Dao and colleagues, in a multicentre observational Teratology Information Services cohort study in BMJ Open in 2024, found no pattern of congenital anomalies in women with first-trimester GLP-1 receptor agonist exposure. Cesta and colleagues, writing in JAMA Internal Medicine in 2024, also found no significantly increased risk of major congenital malformations in a comparative safety study. These findings do not constitute safety clearance: the studies are observational, sample sizes are limited, and long-term developmental outcomes have not been studied. No pattern of congenital anomalies was detected in these limited samples, but absence of a detected signal is not evidence of safety. [Human observational]

• Clinical consensus on pregnancy: Stop upon pregnancy confirmation. Varughese, writing in Clinical Medicine in 2025, clinical consensus on GLP-1 discontinuation. Parker and colleagues, in a 2025 review in Diabetes, Obesity & Metabolism, confirmed that no GLP-1 agent is cleared for pregnant or breastfeeding women based on current regulatory clinical trial safety data. Muller and colleagues, in a 2023 systematic review in Frontiers in Endocrinology, broadly supported advising discontinuation of GLP-1 agents during pregnancy and lactation. [Human observational]

• Tirzepatide-specific pregnancy guidance: Discontinue before planned pregnancy. Current FDA-approved prescribing information for tirzepatide (Mounjaro and Zepbound, Eli Lilly) recommends discontinuation at least 2 months before planned pregnancy, reflecting the compound's longer half-life relative to other GLP-1 class agents. The LactMed database entry on tirzepatide (NIH National Library of Medicine, 2026 update) summarizes this labeling guidance alongside the limited available human lactation data. Verify current prescribing information at dailymed.nlm.nih.gov before any clinical decision. The tirzepatide prescribing information notes caution is warranted during breastfeeding, particularly for newborns and preterm infants. [Human observational / prescribing information]

• Breastfeeding data: Preliminary signal, not regulatory clearance. Diab and colleagues, writing in Nutrients in 2024, reported that subcutaneous semaglutide was not detected in human milk samples in their small-cohort study, with the projected relative infant dose below the conventional 10% safety threshold used in lactation pharmacology. This preliminary signal is hypothesis-generating. The study is preliminary and small, and no regulatory authority has cleared semaglutide or any GLP-1 agent for use while breastfeeding. Kettner and colleagues, in a 2025 review in Journal of Pharmacy Practice, recommend a conservative approach and advise avoiding GLP-1 agents during lactation. [Human observational]

• Emerging research context: Not yet sufficient for clinical endorsement. Hanif and colleagues, in a 2025 observational analysis in American Journal of Cardiology, reported preliminary comparative data on GLP-1 receptor agonist use in first-trimester pregnant women with type 2 diabetes, reporting no statistically detectable difference in maternal mortality, gestational hypertension, preeclampsia, or fetal cardiac/kidney anomaly rates between exposed and control cohorts in their sample. This is a non-randomized observational finding; sample size and duration are insufficient to establish safety, and the study does not alter the current clinical consensus to discontinue GLP-1 receptor agonists upon pregnancy confirmation. These findings are hypothesis-generating and contextualizing, not clinically endorsing. [Human observational (preliminary) / Animal data]

Growth hormone secretagogues (sermorelin, CJC-1295, ipamorelin) and tesamorelin

Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy and carries PLLR-compliant pregnancy and lactation labeling that should be consulted directly. Sermorelin acetate was previously FDA-approved (Geref Diagnostic, now discontinued); it is currently available only through Section 503A compounding. CJC-1295 and ipamorelin have no FDA-approval history and are available only through compounding. The lactation and pregnancy data gaps described below apply specifically to the compounded forms; tesamorelin users should consult current FDA labeling for the approved product.

• Pregnancy and breastfeeding data: None for compounded GH secretagogues. Falutz and colleagues' long-term tesamorelin study, published in AIDS in 2008, noted that tesamorelin is not indicated in pregnancy. Sigalos and Pastuszak, in their 2018 GH secretagogue safety review, confirmed that no reproductive safety studies exist for any GH secretagogue. The role of IGF signaling in normal fetal development — documented by Bowman et al. (2010) — means that GH axis stimulation during pregnancy introduces theoretical developmental risks in the absence of human safety data. [Insufficient data] Clinical posture: Compounded GH secretagogues (sermorelin, CJC-1295, ipamorelin) are not FDA-approved and carry no PLLR-compliant pregnancy or lactation safety data. Absent any evaluated pregnancy or lactation safety profile, and given that IGF signaling is active in fetal development and lactation physiology, the appropriate clinical posture is avoidance during pregnancy and breastfeeding. This reflects absence of data and mechanistic concern, not a compound-specific risk evaluation. Tesamorelin users should consult current FDA labeling for the approved product.

Unapproved injectable peptides marketed as "research use only" (BPC-157, TB-500, and similar)

BPC-157, TB-500, and similar compounds are not FDA-approved for any indication and are not lawfully marketed for human use. Some vendors label these products "for research use only" or "not for human consumption" — a labeling pattern the FDA has characterized in warning letters as an intended-use disclaimer that does not defeat the actual intended use established by surrounding marketing. No reproductive toxicology data exists for any of these compounds in pregnant or lactating humans, and the unregulated supply chain introduces additional unknowns around identity, purity, and dosing. As of February 2026, BPC-157 and TB-500 are subject to FDA actions restricting their availability through compounding pharmacies; their current status should be verified against FDA's 503A bulk drug substances list before any clinical discussion.

• Pregnancy and breastfeeding data: None. Most unapproved therapeutic peptides have no reproductive toxicology data, reflecting the absence of FDA-mandated preclinical studies. No controlled studies of BPC-157, TB-500, or similar compounds in pregnant or breastfeeding populations exist in the published literature. [Insufficient data] Clinical posture: These compounds are not FDA-approved and carry no PLLR-compliant pregnancy or lactation safety data. Absent any evaluated pregnancy or lactation safety profile, and given unregulated supply-chain risks, the appropriate clinical posture is avoidance during pregnancy and breastfeeding. This reflects absence of data and mechanistic concern, not a compound-specific risk evaluation.

Peptides sold through online vendors as "research use only" or "not for human use" are not regulated by the FDA for quality, purity, or potency. For a pregnant or breastfeeding individual, the risks of unregulated product quality compounds the already-insufficient evidence base for the compound's intended pharmacology. There is no way to distinguish compound effects from contaminant effects without pharmaceutical-grade sourcing and controlled study conditions. Colalto, writing in Regulatory Toxicology and Pharmacology in 2024, noted that impurities in unregulated peptide products can cause unexpected adverse reactions at doses that would otherwise be tolerable.

The Endogenous Peptide Context

Not all peptides carry the same risk profile. The body's own peptide hormones regulate critical aspects of pregnancy and lactation. Endogenous GLP-1 is detectable in normal pregnancies and participates in maternal glucose regulation, suggesting that GLP-1 receptor signaling has genuine developmental roles. Uvnäs Moberg et al. documented that endogenous oxytocin, a peptide hormone, is central to breastfeeding physiology. These findings mean that pharmacologically manipulating GLP-1 or GH pathways during pregnancy or lactation has the potential to interfere with established physiological processes, even if the specific harmful mechanism is not yet defined in human data.

Separately, preclinical animal research has suggested that GLP-1 peptide analogs might have anti-inflammatory effects in certain inflammatory conditions. This preclinical context illustrates the mechanistic complexity of this space: the same compound class may have both potential benefits and potential harms depending on context, timing, and dose. Clinical context does not resolve that complexity for an individual patient; it requires individualized clinical judgment.

Who Should Not Use Therapeutic Peptides During Pregnancy or Breastfeeding

The general recommendation is straightforward: avoid any non-insulin therapeutic peptide during pregnancy or breastfeeding unless the prescribing provider and OB/GYN have evaluated your specific situation and determined that the clinical benefit outweighs the data gap risk.

• Individuals planning pregnancy: For GLP-1 receptor agonists, discontinue upon pregnancy confirmation at minimum; for tirzepatide, at least 2 months before planned conception. For GH secretagogues, discuss discontinuation timing with your provider. [Human observational / prescribing information]
• Pregnant individuals: No GLP-1 receptor agonist, GH secretagogue, or research peptide is cleared for use in pregnancy. The only peptide class with established pregnancy safety data is insulin, used for an approved indication. [Insufficient data for all non-insulin classes]
• Breastfeeding individuals: No GLP-1 agent or GH secretagogue is cleared for breastfeeding. Preliminary semaglutide milk-pharmacokinetic data exists but is hypothesis-generating and does not support clinical use during lactation. [Insufficient data]
• Individuals using unregulated research peptides: No reproductive toxicology data exists for any research-use-only compound. The combination of unknown compound effects and uncontrolled product quality makes any risk-benefit evaluation impossible. [Insufficient data]

Drug Interactions in Pregnancy Context

Drug interaction considerations during pregnancy and breastfeeding extend beyond the direct compound-to-compound pharmacology framework relevant in non-pregnant adults. The following are the most relevant interaction considerations:

• GLP-1 receptor agonists and diabetes medications in pregnancy: Pregnant individuals with diabetes who have been using GLP-1 agents alongside insulin or oral hypoglycemics face a transition to insulin-only management upon discontinuation of the GLP-1 agent. This requires provider-managed dose adjustment. [Human observational — prescribing information]
• GH secretagogues and glucose-regulating medications: GH-axis activation is known from endocrine physiology to increase hepatic glucose output and reduce insulin sensitivity. Compounded GH secretagogues (sermorelin, CJC-1295, ipamorelin) are not FDA-approved and have no PLLR-compliant pregnancy labeling; the concern here reflects underlying GH/IGF-1 axis physiology rather than a compound-specific interaction profile. No evidence supports continuation during pregnancy. [Human observational]

When to Seek Medical Attention

The circumstances in which a pregnant or breastfeeding individual using a therapeutic peptide should seek immediate provider attention are not limited to the compound-specific adverse event profile.

Seek immediate emergency care

• Any symptom consistent with anaphylaxis or severe allergic reaction (swelling, breathing difficulty, rapid loss of blood pressure).
• Severe abdominal pain — a possible pancreatitis signal in GLP-1 receptor agonist users, particularly concerning in a pregnant individual.
• Signs of hypoglycemia (confusion, diaphoresis, trembling, loss of consciousness) in individuals transitioning from GLP-1 agents to insulin during pregnancy.

Contact your OB/GYN and prescribing provider within 24 hours

• Any unexpected symptom appearing after peptide injection during pregnancy or breastfeeding, including new nausea, vomiting beyond first-trimester nausea patterns, or unusual fatigue.
• Any concern about whether the peptide may be affecting fetal movement or development — this requires clinical evaluation, not self-assessment.
• Discovery of pregnancy while currently using any therapeutic peptide — this is an immediate provider contact situation, not one to wait on.

Which Biomarkers Are Relevant in This Context?

Biomarker monitoring during pregnancy requires obstetric provider interpretation and integration with standard prenatal monitoring. The following markers are relevant to understanding the physiological context of peptide use in pregnancy or the transition off peptide therapy:

• Fasting glucose and HbA1c: Central to managing glucose metabolism during pregnancy, particularly for individuals transitioning off GLP-1 receptor agonists to insulin-based management. Fasting glucose and HbA1c trends establish the glycemic baseline relevant to managing glucose metabolism before pregnancy and during the provider-supervised transition off any therapeutic peptide before or upon pregnancy confirmation.
• IGF-1: Relevant if GH secretagogues were in use prior to pregnancy and as a baseline for understanding GH axis status. Maternal-placental IGF signaling is physiologically active in pregnancy; a baseline IGF-1 measurement provides reference data for provider interpretation.
• Liver enzymes (GGT/ALT): Baseline hepatic function is relevant context for any compound use during pregnancy, where hepatic physiology changes throughout gestation. A pre-treatment or pre-pregnancy liver enzyme baseline supports interpretation of any changes.
• hs-CRP: Systemic inflammation baseline. High-sensitivity CRP is physiologically elevated in normal pregnancy; a pre-pregnancy or first-trimester baseline distinguishes pathological from expected elevation.

Understanding Your Baseline

For anyone considering pregnancy while using a therapeutic peptide, establishing a comprehensive metabolic baseline before conception is the most clinically useful preparatory step. Glucose metabolism, liver function, and inflammatory markers provide the reference context for evaluating any changes during pregnancy and for managing the transition off therapeutic peptides where indicated.

The principle underlying that approach is foundational to Superpower's approach to preventive health: objective data before intervention creates the reference point that makes clinical decisions interpretable. In the context of pregnancy, that principle applies with even more weight, because clinical decisions affect two individuals, not one.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a class in the context of pregnancy and breastfeeding. Individual peptides vary significantly in regulatory status, safety profile, and clinical evidence. Some peptides discussed are FDA-approved prescription medications; others are available only through compounding pharmacies; others are not approved for human use. This content does not constitute medical advice for any specific compound or clinical situation.

Do not start, stop, or modify any peptide therapy during pregnancy or breastfeeding without consulting a qualified healthcare provider, including your OB/GYN. Decisions about medication use during pregnancy and breastfeeding require individualized clinical evaluation of risks and benefits specific to your situation.

If you are using a peptide obtained from an unregulated source, be aware that product quality, purity, and accuracy of dosing cannot be verified without pharmaceutical-grade standards. Contaminated or mislabeled products may cause adverse effects not described in the clinical literature for the intended compound. Use of unregulated compounds during pregnancy or breastfeeding carries compounded risk.

If you experience symptoms consistent with a serious adverse event during pregnancy or breastfeeding, seek emergency medical care immediately and inform your care team of all medications and compounds you have used.

For information about FDA-approved prescription peptides, prescribing information is available at dailymed.nlm.nih.gov. For regulatory information about specific compounds, see fda.gov.

Disclaimer: This page is provided by Superpower Health for educational and informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider.